Meet the team

Mikkel Wandahl Pedersen, PhD

CEO & CSO

Mikkel is an experienced human biologist with 20 years of expertise in biologic drug discovery and development. He holds a PhD in Cancer Biology from the University of Copenhagen and has a comprehensive background in antibody-based drug discovery and development within therapeutic areas such as oncology, autoimmune diseases and infectious diseases. He has extensive knowledge of the entire drug discovery process, from target identification and lead selection through pre-clinical development and clinical evaluation. He has played pivotal roles in bringing more than 10 different therapeutic programs from ideation through to clinical development.


Mikkel has held senior leadership positions, most recently serving as Chief Scientific Officer (CSO) for Nykode Therapeutics, and before that serving as CSO for Symphogen in Denmark. His strong national and international scientific network extends across academia and industry. Mikkel is also a co-author of over 40 peer-reviewed publications.

Dennis V. Pedersen, PhD

COO & Co-founder

Dennis has studied the relationship between structure and function of complement proteins for more than 10 years. Dennis has a PhD from Aarhus University in Denmark and has extensive experience within drug development and project management from academic collaborations and biotech industry. Prior to founding Commit, Dennis has worked with structure-based drug discovery at Muna Therapeutics.

Nick S. Laursen, PhD

Head of Discovery & Co-founder

Nick has extensive experience in antibody characterization and has worked within the field of complement research for more than 15 years. Prior to founding Commit, Nick worked as an Associate Professor at Aarhus University in Denmark where he, together with the other founders, developed the BiCE™ technology.

Mikael Winkler, PhD

Head of Platform Technology & Co-founder

Mikael has a PhD from Aarhus University in Denmark where he studied the structure and function of membrane proteins. He has extensive experience within structural biology, and his work on cholesterol and auxin transporters has been published in the high impact journals Nature and Cell. Following his PhD, Mikael worked together with the other founders on developing the BiCE™ technology.

Heidi Gytz Olesen, PhD

Head of Drug Screening & Co-founder

Heidi has a broad background within the field of molecular biology and obtained her PhD from Aarhus University, where she studied replication of RNA viruses. Heidi has led several industrial research collaborations studying the complement system, including projects for Complement Pharma, Alexion Pharmaceuticals and Argenx.

Kevin Hollevoet, PhD

Project manager

Kevin is a seasoned venture builder and operator, passionate about bringing transformative science to patients. After completing his PhD at Ghent University and a postdoc on antibody-drug conjugates at the US National Cancer Institute, Kevin built and directed a DNA-based antibody platform at KU Leuven. Since transitioning to industry in 2018, Kevin has collaborated with academic founders, investors, and biotech firms around the globe to unleash therapeutic innovations in various indications, leveraging both single assets and platform technologies.

Kristin Mørk Rolin

HR Business Partner & Executive Assistant

Kristin holds a master's degree in communications from Roskilde University in Denmark and has extensive experience in HR, internal communications, and organizational development from a range of sectores including finance, law, and biotechnology. Most recently, Kristin has supported leadership teams in navigating complex change processes and driving organizational transformation at Norwegian Nykode Therapeutics. 

At Commit Biologics, Kristin is dedicated to developing people and improving organizational performance. She serves as a trusted advisor to senior management and builds strong partnerships to enable, lead and accelerate change processes that deliver measurable and lasting impact.